Comparing the current results to its competitors, Ispecimen Inc reported Revenue decrease in the 2 quarter 2026 year on year by -78.69 %, despite the revenue increase by the most of its competitors of 16.1 %, recorded in the same quarter.
Ispecimen Inc 's Comment on Competition and Industry Peers
The company operates in a fragmented market for human biospecimens, competing with healthcare providers, commercial biobanks, specimen brokers, and commercial specimen providers. Most providers hold less than 5% market share, with no single entity exceeding 20%. Larger providers, often supported by private equity, are consolidating the industry by acquiring smaller firms to expand specimen access and research subject availability. These larger providers pose the primary competitive threat due to their extensive specimen access, existing inventories, and financial resources, despite lacking a technology-based approach. The company’s technology-based platform, iSpecimen Marketplace, aims to provide a competitive advantage by facilitating faster scaling and a more integrated purchasing experience. Additional competition arises from healthcare providers with in-house biospecimen inventories offering lower prices, commercial biobanks with ready inventories, and specimen brokers specializing in niches such as infectious disease.
March 5, 2024
iSpecimen Inc. (Nasdaq: ISPC), the pioneering online marketplace connecting scientists with healthcare specimen providers for research purposes, has announced that it will unveil its full year financial results for the period ending December 31, 2023, on March 13, 2024, as per the latest report. The company s headquarters in Lexington, Massachusetts, is buzzing with anticipation as stakeholders eagerly await the release of these results.iSpecimen is globally recognized for its innovative platform, which seamlessly connects researchers with a vast network of healthcare providers, ensuring quick and reliable access to the biospecimens required for critical medical research. By bridging the gap between healthca...
January 23, 2024
iSpecimen, a leading supplier of human biospecimens, and TriMetis Life Sciences, a pioneer in digital AI histopathology services, have announced a strategic partnership aimed at revolutionizing tissue-based research. By leveraging cutting-edge technology and expertise, these two companies aim to optimize quality control and assurance, ultimately enhancing the efficiency and accuracy of histopathology services.Histopathology plays a crucial role in the field of medical research, as it involves the analysis of tissue samples to diagnose diseases and provide critical insights into patient care. However, traditional histopathology processes are often time-consuming, labor-intensive, and subject to human error. T...
In an endeavor to advance the field of oncology research, iSpecimen Inc has reinforced its global biospecimen offering by adding new suppliers and expanding existing relationships. This strategic move aims to provide researchers with increased access to highly-sought-after biospecimens, thereby stimulating innovation and expediting breakthroughs in cancer treatment and understanding. iSpecimen Inc, a leader in the biospecimen procurement industry, remains at the forefront of facilitating crucial collaborations between researchers, healthcare organizations, and suppliers. By continually expanding their supplier network, iSpecimen strengthens its position as a preferred partner for those seeking ...
Quest Diagnostics Inc operates as a leading provider of clinical laboratory and diagnostic information services, catering to patients, healthcare professionals, hospitals, and pharmaceutical companies. The company generates revenue through a comprehensive suite of diagnostic testing services, encompassing routine lab tests, advanced molecular diagnostics, and a variety of specialized tests tailored to support clinical decision-making and patient care.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Labcorp Holdings Inc operates as a major healthcare diagnostics company, providing clinical laboratory tests and services to healthcare providers, pharmaceutical companies, and government agencies. Their business model emphasizes delivering accurate and timely test results to aid in patient diagnosis, treatment, and monitoring.
Sources:
Ispecimen inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ispecimen inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
